Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019

SELL
$11.11 - $25.6 $42,384 - $97,664
-3,815 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$11.75 - $21.42 $7.77 Million - $14.2 Million
-660,970 Reduced 99.43%
3,815 $48,000
Q3 2018

Nov 14, 2018

SELL
$19.26 - $23.46 $6.02 Million - $7.33 Million
-312,641 Reduced 31.99%
664,785 $14.3 Million
Q1 2018

May 15, 2018

BUY
$18.89 - $32.46 $3.59 Million - $6.17 Million
190,166 Added 24.16%
977,426 $24.6 Million
Q4 2017

Feb 14, 2018

BUY
$16.19 - $20.3 $10.9 Million - $13.6 Million
671,346 Added 579.18%
787,260 $15 Million
Q3 2017

Nov 14, 2017

BUY
$15.52 - $18.94 $1.8 Million - $2.2 Million
115,914
115,914 $0

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $258M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Aviva Holdings Ltd. Portfolio

Follow Aviva Holdings Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviva Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Aviva Holdings Ltd. with notifications on news.